Keyphrases
Brentuximab Vedotin
100%
Indoleamine 2,3-dioxygenase 1 (IDO1)
96%
Urothelial Cancer
96%
Dendritic Cells
84%
Bladder Cancer
72%
T Cells
59%
Cutaneous Toxicity
52%
Antibody-drug Conjugate
37%
Chronic Inflammation
36%
Nectin-4
36%
Pancreatic Ductal Adenocarcinoma
33%
Cisplatin
31%
Tumor Progression
30%
Advanced Urothelial Cancer
28%
Overall Survival
28%
Immune Privilege
27%
Interferon-α (IFN-α)
26%
Non-muscle Invasive Bladder Cancer (NMIBC)
25%
Bacillus Calmette-Guérin Unresponsive
25%
Interleukin-6
25%
Regulatory T Cells
25%
Tumor
25%
Pancreatic Tumor
24%
Mitomycin C
24%
Lymphoid Cells
24%
Acquired Immune Response
24%
Toxicity Response
24%
Resectable Pancreatic Cancer
24%
Physiologic Control
24%
Response Mechanism
24%
Neoantigen
24%
Irinotecan
24%
Immune Suppression
24%
Gene Therapy
24%
Lentiviral
24%
Bacillus Calmette-Guérin
24%
Splenic Dendritic Cell
24%
External Beam Radiotherapy
24%
Sorafenib
24%
Phospho-Akt
24%
Durvalumab
24%
Single-center Experience
24%
Cancer Research Network
24%
Phase 1 Trial
24%
Tumor Immunity
24%
Immunomodulatory
24%
Resistance Mechanisms
24%
Radiological Response
24%
Olaparib
24%
Tumor Immunogenicity
24%
Medicine and Dentistry
T Cell
53%
Bladder Cancer
51%
Dendritic Cell
48%
Neoplasm
35%
B Cell
34%
Bladder
30%
Cystectomy
28%
Urothelial Cancer
28%
Overall Survival
27%
Gene Expression Profiling
27%
Interferon
26%
Antibody-Drug Conjugate
26%
Nectin
26%
Mycobacterium Bovis BCG
25%
Non Muscle Invasive Bladder Cancer
25%
Lymphoid Cell
24%
Immune Checkpoint Inhibitor
24%
Pancreas Adenocarcinoma
24%
Durvalumab
24%
Pancreas Tumor
24%
Gene Therapy
24%
Squamous Cell Carcinoma
24%
Cancer Research
24%
Interferon Alfa
24%
Indoleamine 2,3 Dioxygenase
24%
External Beam Radiotherapy
24%
Tumor Immunogenicity
24%
Docetaxel
24%
Cisplatin
24%
Chronic Granulomatous Disease
24%
Gemcitabine
24%
Sarcomatoid
24%
Prostate Adenocarcinoma
24%
Enfortumab Vedotin
21%
Toll Like Receptor 9
19%
Transitional Cell Carcinoma
18%
Regulatory T Cell
17%
Immunotherapy
17%
Transcriptome
14%
Ligation
13%
RNA Sequence
13%
Malignant Neoplasm
12%
Stroma
11%
Muscle Invasive Bladder Cancer
10%
Immunity
9%
Intravesical Drug Administration
9%
Immunocompetent Cell
8%
Disease
7%
Drug Megadose
7%
Prostate Tissue
7%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
76%
Bladder Cancer
48%
Enfortumab
48%
Cisplatin
48%
Enfortumab Vedotin
43%
Neoplasm
32%
Antibody Drug Conjugate
28%
Nectin
28%
Overall Survival
26%
Skin Toxicity
26%
Mycobacterium Bovis BCG
25%
Non Muscle Invasive Bladder Cancer
25%
Gemcitabine
24%
Irinotecan
24%
Mitomycin
24%
Tumor Growth
24%
Differentiated Thyroid Cancer
24%
Pancreas Cancer
24%
Docetaxel
24%
Chronic Inflammation
24%
Chronic Granulomatous Disease
24%
Durvalumab
24%
Transcriptome
24%
Interferon
24%
Indoleamine 2,3 Dioxygenase
24%
Olaparib
24%
Sorafenib
24%
Alpha Interferon
24%
Prostate Adenocarcinoma
24%
12-O-Tetradecanoylphorbol-13-Acetate
20%
Pancreas Adenocarcinoma
15%
Progression Free Survival
10%
RNA-Sequencing
9%
Chemotherapy
9%
Radioactive Iodine
9%
Biological Marker
8%
Prostate Cancer
7%
Transitional Cell Carcinoma
7%
Adverse Event
7%
Inflammation
6%
Combination Therapy
6%
Monotherapy
6%
Maximum Tolerated Dose
6%
Myelodysplastic Syndrome
6%
Neutropenia
5%